Key Takeaways
- Cencora announced the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion
- Upon completion of the transaction, the retina physicians of EyeSouth Partners will join Retina Consultants of America
- The aim is to enhance access to advanced retina care, clinical trials, and research by expanding Retina Consultants of America’s network and capabilities
Cencora announced the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora’s Retina Consultants of America (RCA), a management services organization.
“Driven by a commitment to empower ophthalmologists, EyeSouth Partners has built a strong regional network of physicians that provides high-quality patient care,” said Robert P. Mauch, president and chief executive officer of Cencora. “By joining RCA, these physicians will become part of an organization with capabilities designed to provide world-class retina care and be supported by Cencora’s long-standing commitment to community physicians.”
“We look forward to collaborating with the well-trained and respected EyeSouth Partners’ physicians as we work together to advance sight-saving treatment for patients,” said David Brown, MD, chief medical officer, RCA.
“We are excited to be joining RCA, which shares our commitment to delivering exceptional care and advancing the fight against blindness,” said Atul Sharma, MD, EyeSouth Partners board member. “Our physicians will drive expanded access to innovative treatments through RCA’s clinical trial and research offerings while continuing to work with EyeSouth Partners to support patient access across the ophthalmology landscape.”
Cencora expects the acquisition to be slightly accretive, net of financing costs, to its adjusted diluted earnings per share in the first 12 months following transaction closing. The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. Cencora’s reaffirmed fiscal 2026 financial guidance does not currently contemplate the transaction closing in its fiscal 2026.
